Catalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients with Congenital Myasthenic Syndromes

CORAL GABLES, Fla., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases,...
Source: - New Drug Applications - Category: Drugs & Pharmacology Source Type: news

Related Links:

AbstractNocebo refers to the adverse events (AEs) experienced when taking a placebo drug and is believed to be a centrally mediated process. We sought to examine the AEs following placebo administration in Randomised Controlled Trials (RCTs) for Myasthenia Gravis (MG) patients. A systematic literature search was performed on Medline and Web of Science for RCTs for MG pharmacological treatments. We assessed the number of placebo-treated patients reporting at least one AE and the number of dropouts because of AEs. Data were extracted from six RCTs fulfilling the search criteria. Four out of five placebo-treated participants ...
Source: Acta Neurologica Belgica - Category: Neurology Source Type: research
Therapeutic plasma exchange (TPE) is a process in which plasma containing antibodies, immune complexes, inflammatory moderators, paraproteins and other toxins which are believed to be the cause of disease is removed from a patient. TPE is the first-line treatment (category I, level 1A) in all forms of Acute inflammatory demyelinating polyradiculoneuropathy disease (axonal, demyelinating and miller-fisher variant) as well as in acute myasthenic crisis, chronic inflammatory demyelinating polyradiculoneuropathy and Paraproteinemic neuropathies(category I, level 1B).
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
Condition:   Generalized Myasthenia Gravis Interventions:   Biological: Ravulizumab;   Drug: Placebo Sponsor:   Alexion Pharmaceuticals Recruiting
Source: - Category: Research Source Type: clinical trials
This study was carried out in accordance with the recommendations of “NIH Guide for Care and Use of Laboratory Animal protocols” and of the Institutional Animal Care and Use Committee of Shiga University of Medical Science (SUMS). The protocol was approved by SUMS. Six adult male Balb/c mice (5-weeks-old) were purchased from Clea Japan Inc. (Konan, Japan). Each mouse (labeled H1-H6) received subcutaneous injections of 0.1 ml of TiterMax Gold adjuvant (Sigma-Aldrich, Saint-Louis, MO, USA) containing 5 mg/ml KLH-conjugated peptide into multiple sites of the neck and back skin with at a 2-week interval. Antisera, ...
Source: Frontiers in Neuroanatomy - Category: Neurology Source Type: research
We describe here a powerful method for identifying B cells that recognize membrane antigens expressed on cells. The technique depends on two characteristics of the interaction between a B cell and an antigen-expressing cell: antigen-receptor-mediated extraction of antigen from the membrane of the target cell, and B cell activation. We developed the method using influenza hemagglutinin as a model viral membrane antigen, and tested it using acetylcholine receptor (AChR) as a model membrane autoantigen. The technique involves co-culturing B cells with adherent, bioorthogonally labeled cells expressing GFP-tagged antigen, and ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Condition:   Myasthenia Gravis Interventions:   Drug: Salbutamol 4Mg Tablet;   Drug: Placebo oral capsule Sponsor:   University of Aarhus Recruiting
Source: - Category: Research Source Type: clinical trials
More News: Clinical Trials | Drugs & Pharmacology | Myasthenia Gravis | New Drug Applications